R&D Ipsen on neurotoxin research: the pharmaphorum podcast For episode 7 of the pharmaphorum podcast I spoke to Ipsen’s Philippe Picaut about neurotoxin research, with a particular focus on Botulinum neurotoxins.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.